Amigrenin

Amigrenin - antimigraine agent.

Release form and composition

The medicine is produced in the form of coated tablets, each of which contains:

• 50 or 100 mg of sumatriptan (as sumatriptan succinate);
• Such excipients as lactose, sodium carboxymethyl starch, microcrystalline cellulose, magnesium stearate, potato starch.

The shell includes: macrogol 4000, titanium dioxide, talc, povidone, hypromellose.

Implemented tablets of 2 pcs. in blisters, arranged in cartons.

Indications for use Amigrenina

As indicated in the instructions for Amigrenin, this drug is intended for the relief of acute migraine attacks (both without and with aura).

Contraindications

According to the annotation to the drug, the use of Amigrenin is contraindicated in patients with:

• Hemiplegic, ophthalmoplegic and basilar form of migraine;
• Uncontrolled arterial hypertension;
• Occlusive peripheral arterial disease;
• Ischemic heart disease;
• Severe impaired liver function;
• Stroke or transient cerebral circulation (in history including).

Also taking Amigrenin is prohibited:

• For the prevention of migraine;
• Pregnant women;
• During lactation;
• Children and teenagers under 18;
• Older people (over 65);
• In the presence of hypersensitivity to sumatriptan or any auxiliary component of the drug;
• Simultaneously with MAO inhibitors and within 14 days after their cancellation;
• Simultaneously with medicines, which include ergotamine or its derivatives.

Dosage and dosage Amigrenina

Amigrenin tablets, according to the instructions, take orally. A single dose is 50-100 mg, the maximum daily allowance is 300 mg.

If, after taking the first dose, the symptoms of migraine do not even diminish, you can take the second dose to stop an ongoing attack. If the symptoms have passed or decreased, but after some time have resumed, a second dose can be taken within the next days. The minimum interval between taking pills is 2 hours.

Side effects Amigrenina

Reviews of patients who took Amigrenin, suggest that this drug may have side effects, such as:

• Nausea, dysphagia, vomiting, discomfort in the abdomen, extremely rare - increased activity of liver enzymes, ischemic colitis;
• Drowsiness, dizziness, feeling of increased fatigue, weakness, visual disturbances (decrease in sharpness, scotoma, diplopia);
• Tachycardia, bradycardia, hyperemia of the mucous membranes and skin, rapid heartbeat, hypotension, angina, transient ECG changes in ischemic type, transient increase in blood pressure, in individual cases - Raynaud's syndrome;
• Skin rash, urticaria, erythema, pruritus, anaphylaxis.

Also Amigrenin, according to reviews, can cause myalgia, a feeling of heaviness, heat, tingling, compression or pressure in different parts of the body.

special instructions

When administering Amigrenin and, in general, drugs based on sumatriptan for the first time to patients, as well as for migraines, the attacks of which occur with atypical symptoms, it is important to conduct an additional examination in order to exclude other potentially dangerous neurological diseases. It is also important to remember that people with migraine are at risk of developing cerebrovascular complications (including transient cerebral circulatory disorders and stroke).

If after one or two doses of the drug therapeutic effect is absent, you should consult a doctor to clarify the diagnosis.

One of the side effects of the drug is drowsiness, increased fatigue and visual impairment, for this reason, during the period of Amigrenin use, you should completely give up whenever possible or at least take great care when driving and performing potentially dangerous tasks that require visual acuity and psychomotor speed .

Patients at risk of developing cardiovascular disease, before the appointment of Amigrenin should exclude the presence of the disease, and the first 2-3 intakes of tablets should be carried out under medical supervision, since coronary artery spasm is possible.

Sumatriptan is forbidden to use at the same time with drugs containing ergotamine, as long-term vasospasm may occur. For this reason, Amigrenin can be taken at least a day after the last dose of ergotamine.

The simultaneous use of Amigrenin and selective serotonin reuptake inhibitors is not recommended. Although not a lot of negative cases have been registered, there have been complaints about a person’s lack of coordination, development of weakness and hyperreflexia.

It is forbidden to combine Amigrenin with lithium preparations.

Patients who are hypersensitive to sulfonamides, sumatriptan can cause an allergic reaction, up to anaphylactic shock.

With extreme caution and under the constant supervision of a physician, this anti-migraine drug is prescribed to people with epilepsy and any conditions characterized by a decrease in the threshold of convulsive readiness.

Analogs Amigrenina

Structural analogues (with the same active ingredient) Amigrenina are Imigran, Migrepam, Sumamigren, Sumarin, Sumatriptan, Sumigran, Sumitran, Rapimed, Trimigren.

According to belonging to the same pharmacological subgroup and similarity of the mechanisms of action, the following drugs can be considered analogues of Amigrenin: Zomig, Naramig, Relpaks, Frovamigran.

Terms and conditions of storage

Amigrenin is a list B drug released from pharmacies strictly on prescription. It has a shelf life of 2 years, subject to the storage guidelines recommended by the manufacturer - dry, cool and protected from direct sunlight.